Literature DB >> 34692409

Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China.

Chun-Li Lu1, Ruo-Xiang Zheng1, Xue Xue1,2,3, Xiao-Wen Zhang1, Xue-Han Liu1, Xin-Yan Jin1, Feng-Lan Pu1, Hui-Di Lan1,4, Min Fang1, Ling-Yao Kong1, Merlin Willcox5, Bertrand Graz6, Joelle Houriet6, Xiao-Yang Hu1,4,7, Jian-Ping Liu1.   

Abstract

BACKGROUND: We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China.
METHODS: The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes.
RESULTS: The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19.
CONCLUSION: We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.
© 2021 Korea Institute of Oriental Medicine. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; Mental health; Online survey; Respiratory symptoms; Traditional Chinese medicine

Year:  2021        PMID: 34692409      PMCID: PMC8524811          DOI: 10.1016/j.imr.2021.100798

Source DB:  PubMed          Journal:  Integr Med Res        ISSN: 2213-4220


Introduction

Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until September 13th 2021, there have been more than 224 million confirmed cases, including 3 million deaths reported on the World Health Organisation website. Most people diagnosed with COVID-19 experienced mild to moderate respiratory illness and the most common symptoms include fever, dry cough and tiredness2, 3, 4, 5, 6, 7. As for current treatments of COVID-19 patients with mild symptoms, WHO guidelines recommend that they should be isolated and given symptomatic treatment including antipyretics for fever and pain, adequate nutrition and appropriate rehydration. Differing from WHO guidelines, Chinese guidelines recommend not only symptomatic and anti-viral treatments, but also traditional Chinese medicine (TCM) such as Qingfeipaidu Decoction and Hanshiyi Decoction6, 7. For people with severe or critical COVID-19, current evidence indicates that corticosteroids, remdesivir, hydroxychloroquine, lopinavir/ ritonavir and interferon may have some effects on overall mortality, initiation of ventilation and duration of hospital stay,10, 11, 12, 13. For public health and suspected cases, quarantine is an effective way to reduce the transmission of COVID-19 and other pandemics. Other behavioural control methods, such as physical distancing, wearing a mask, hand washing, keeping rooms well ventilated, avoiding crowds, and coughing into a bent elbow or tissue could also be effective. At the same time, nearly 300 vaccines are being developed, among which eight have been used worldwide. In China, there are mainly three categories of vaccines with completion of over two billion doses of vaccination, including inactivated SARS-CoV-2 vaccine (Vero cell)18, 19, 20, 21, recombinant SARS-CoV-2 vaccine (Type 5 adenovirus vector), and recombinant SARS-CoV-2 vaccine (CHO cell). However, the evaluation of effectiveness and safety of these vaccines are still ongoing, and their impact on mutated virus variants remains to be seen24, 25, 26. TCM has been proved to help enhance the body's resistance (Zheng qi) to infectious diseases based on clinical studies and experiments27, 28, 29. Therefore, considering the need for more evidence, we collaborated with international researchers to investigate behavioural changes, preventative and therapeutic interventions, their occurrence and outcomes among the Chinese population during the COVID-19 pandemic. We aimed to conduct this online cross-sectional survey to show the general situation during the pandemic in China and to indicate the further challenges to fight COVID-19.

Methods

The content of this study is reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement, and the findings are reported following the Checklist for Reporting Results of Internet E-surveys checklist (CHERRIES). The study design and data management method are as follows.

Study design of the survey

An international retrospective survey of prevention, treatment, occurrence and outcomes of COVID-19 in the community (RTO-COVID-19) involving 14 countries was led by researchers at the University of Southampton (UoS) and the University of Geneva. The original survey questions in the English version (available at: https://www.rtocovid19.com) were translated and adapted by authors at Beijing University of Chinese medicine since 10th May, 2020. Localisation was made to reflect the tendency of Chinese people to prevent and cope with diseases, and to adapt to China's anti-epidemic policies and vaccine market. After gaining contact information from the respondents, we also conducted a three-month follow-up questionnaire to acquire more information on peoples’ changes based on this cohort baseline.

Participants

All potential participants were able to access the website of this survey. In those cases where participants were unable to answer the questions themselves, their family members or friends were also invited to help them complete the survey. There was no selective bias on participants. The questionnaire was disseminated by authors and other academic research groups. Inclusion criteria: 1) Any person who could access the questionnaire online; 2) Any person who can read and understand the questionnaire; 3) Person checked "agree" on the informed consent page, to present information on preventive behaviours, treatments taken, symptoms of respiratory illness and their clinical outcomes. 4) There was no restriction on gender. 5) For children (<16 years old), their parents were invited to complete the questionnaire. Exclusion criteria: Persons lacking mental capacity to understand the questionnaire were excluded.

Ethics approval and informed consent

This study received ethical approval from BUCM (2020BZYLL0501, Sep 2020) and from UoS (ERGO 56975, May 2020). All participants were invited to read the overview of the survey. Only those who confirmed consent, by clicking the button “I agree” at the beginning, proceeded to the questions. Participants' contact information was collect. All data collected were managed by the Chinese team.

Development of the survey

Adaptation for Simplified Chinese version

Questions in simplified Chinese version were adjusted to fit the context in China, especially adding more information on TCM. Firstly, machine translation was applied for the original English version questionnaire. Secondly, four authors edited the questionnaire word by word to improve readability. Thirdly, the questionnaire was designed on wjx.cn. Fourthly, all authors piloted the survey with different test scenarios, to improve the logic and wording. This was repeated seven times before the questionnaire was finalized. Questions or answers were changed according to the habits and situation in China, for example, replacing proprietary names of medications (such as "Dafalgan®" to "Tylenol®, "Cetallerg®" to "Zyrtec®") or medical system e.g. Ayurvedic interventions were removed because they are rarely used in China. The content of Chinese patent medicine was expended because of the common use of TCM in China. The Chinese medicines were identified from both national and provincial TCM guidelines to alleviate symptoms of COVID-19, including three versions of national guidelines, Beijing version, three versions of Hunan province, two versions of Guangdong province, Shaanxi province version, Jiangxi province version, Liaoning province version, Sichuan province version, Hebei province version, Gansu province version, Guizhou province version32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48. To reduce the difficulty and time cost of filling the questionnaire, we categorized 132 recommended TCM preparations according to their dosage forms, details in supplementary table 1. With the development of the COVID-19 vaccine, we also added the latest information regarding vaccination.

Pre-test for Simplified Chinese version

The survey was issued on a survey platform wjx.cn. Each person had only one account to answer the questions. The questionnaire was tested by all Chinese authors before dissemination, and considering the different logical relationships between questions. All authors also piloted the questionnaire using different scenarios.

Recruitment process

Disseminating and advertising

The open questionnaire was released on wjx.cn from February 6 to May 19, 2021. The authors forwarded the WeChat post (designed with QR code) to their friends as snowball sampling. The authors contacted five academic organisations to help disseminate the post to more possible respondents. The survey advertisement attached the questionnaire link and the main content of the survey was posted on WeChat subscription account (ebcm2016). People could access from WeChat and Weibo (social platform). Participants who agreed to give their contact details were asked to complete the follow-up questionnaire after three months.

Survey administration

As a public survey platform, wjx.cn is openly accesible in China. When the respondents submitted their answers, they could get a lottery supported by wjx.cn without any conflict of interest. To prevent bias, answers to the questions were arranged in random order. We designed 39 sections including 226 question-items per page, and also added one page of welcome and one page of thanks. Respondents could skip some questions due to the logic and their conditions. Considering the possible multiple options, we only set the informed consent as the mandatory item. Each respondent could review the answers but could not change any content once they submitted.

Data collection and analysis

Summary of data collected

The primary outcomes included a summary of: response rates basic characteristics (physical and mental conditions, COVID-19 impact on social situation) diagnosis (detection of COVID-19 and related respiratory symptoms) treatments and outcomes (for the respiratory symptoms during first and second week) preventive measures The secondary outcomes were similar items from the follow-up questionnaire after three-months, including the response rates, basic characteristics, treatments and outcomes and preventive measures.

Response rates

wjx.cn supported the identification of unique visitors who visited the webpage multiple times with the same IP addresses. wjx.cn could calculate the unique first survey page visitors, participant rate and completion rate. The participants could only be withdrawn by contacting the investigators and asking to be removed from the study. All participants were free to stop at any time and not to complete the survey.

Data analysis

Data were managed in WPS spreadsheet and analysed with wjx.cn (https://www.wjx.cn/). Descriptive analysis was used for basic physical and mental conditions, detection of COVID-19 and related symptoms, treatment for respiratory symptoms, measures to prevent the spread, testing and vaccination of COVID-19, general social information, and the follow-up questionnaire, presented as numbers and percentages. If a questionnaire was collected successfully, we regarded this answer as a complete respondent. Missing data in the analysed items were presented as non-values.

Results

Response rates

The survey was available online from Feb. 6, 2021 to May 19, 2021 and collected a total of 503 visit times, among which 341 (67.8%) submitted their answers. The basic information of the respondents is provided in Table 1. The data were collected from 23 provinces and four municipalities in China (including Taiwan and Hong Kong, no sample from Macao), and we removed the data when the participants were not living in main land China, and distribution map covering 316 respondents’ report is shown in Figure 1, the detailed numbers in supplementary table 2.
Table 1

The basic information of 341 respondents

ItemsSummary data (Number, % / mean difference, range)
Age341 (100.00)
 Mean age33.02±10.25 years (18-70)
 <18 years old0 (0.00)
 18-60 years old326 (95.60)
 >60 years old8 (2.35)
 Not reported7 (2.05)
Gender341 (100.00)
 Men117 (34.31)
 Women224 (65.69)
Weight341 (100.00)
 Mean weight64.63±19.75 kg (41-105)
 Normal range (Self-cognition)209 (61.29)
 Underweight (Self-cognition)24 (7.04)
 Overweight (Self-cognition)84 (24.63)
 Unknown (Self-cognition)24 (7.04)
Height341 (100.00)
 Mean height165.53±8.55 cm (120-198)
Smoking341 (100. 00)
 No smoking316 (92.67)
 Artificial cigarettes24 (7.04)
 Hand-rolled cigarettes1 (0.29)
 Mean smoking amount10.92±6.64 per day (0.5-20)
Drinking341 (100.00)
 No drinking159 (46.63)
 Once a month98 (28.74)
 2 to 4 times a month36 (10.56)
 Unknown48 (14.08)
Eating habits341 (100.00)
 Chinese food208 (61.00)
 Low-glycemic load diet40 (11.73)
 Low carbohydrates34 (9.97)
 Vegetarians29 (8.50)
 No special93 (27.27)
Survey accessed channels341 (100)
 Friends and families196 (57.48)
 Social media (via WeChat platform)97 (28.45)
 E-mail15 (4.40)
 Working organization2 (0.59)
 Unknown31 (9.09)
Pregnant9 (4.02)
Physical / mental conditions (Details in supplementary table 3)341 (100.00)
 Healthy282 (82.70)
 Mental health problems (e.g. Anxiety, depression)17 (4.99)
 Other chronic disease40 (11.73)
 Sub-healthy state1 (0.29)
 Not reported12 (3.52)
Completed the SARS-CoV-2 nucleic acid test290 (85.04)
 egative284 (97.93)
 Positive6 (2.07)
  with COVID-19 symptoms4 (1.38)
  asymptomatic carrier2 (0.69)
Duration of respiratory symptoms when testing290 (85.04)
 With symptoms lasting for <7 days12 (4.14)
 With symptoms lasting for 7∼14 days6 (2.07)
 With symptoms lasting for >14 days4 (1.38)
 No symptoms245 (84.49)
  Not reported23 (6.74)
Antibody testing of COVID-19341 (100.00)
Did not have antibody testing of COVID-19201 (58.94)
Did antibody testing of COVID-19132 (38.71)
 Negative126 (36.95)
 Positive6 (1.76)
Not reported whether have antibody testing of COVID-198 (2.35)
Vaccination341 (100.00)
Flu vaccination in the past two years20 (5.86)
The first dose of COVID-19 vaccination from Nov 2020 to May 202171 (20.82)
 Sinopharm Group25 (35.21)
 Beijing Sinovac22 (30.99)
 Beijing Institute of Biological Products13 (18.31)
 Pfizer/BioNTech5 (7.04)
 Oxford/AstraZeneca5 (7.04)
 Modena1 (1.41)
The second dose of COVID-19 vaccination from Dec 2020 to May 202148 (14.08)
 Sinopharm Group15 (31.25)
 Beijing Sinovac14 (29.17)
 Beijing Institute of Biological Products8 (16.67)
 Pfizer/BioNTech5 (10.42)
 Wuhan Institute of Biological Products4 (8.33)
 Oxford/AstraZeneca2 (4.17)
 Not reported whether have any vaccination224 (65.69)
Different working status during COVID-19 since 2020341 (100.00)
 Working outside105 (30.79)
 Full-time student77 (22.58)
 Some work at home and some work outside61 (17.89)
 Working at home43 (12.61)
 Having a holiday12 (3.52)
 Retirement10 (2.93)
 Unemployment7 (2.05)
 Preparing for the examination1 (0.29)
 Not reported25 (7.33)
Occupations during COVID-19 since 2020341 (100.00)
 Reported155 (45.45)
   Resident medical staff107 (69.03)
  Nursing staff19 (12.26)
  Community health worker9 (5.81)
  Shop/supermarket worker5 (3.23)
  Office clerk5 (3.23)
  Teacher3 (1.94)
  Medical researchers3 (1.94)
  Civil servants1 (0.65)
  Cook1 (0.65)
  Delivery person1 (0.65)
  Engineer1 (0.65)
 Not reported186 (54.55)
COVID-19 Impact on economic situation341 (100.00)
 Great problems14 (4.10)
 Little problems114 (32.84)
 No problems201 (58.94)
 Not reported12 (3.52)
Fig. 1

Respondents distribution map in China according to different provinces.

The basic information of 341 respondents Respondents distribution map in China according to different provinces. As for the follow-up survey after three-months, we sent the questionnaire also via wjx.cn to 155 respondents separately who were willing to be followed up and provided their contact information on July 2, 2021. Finally, 23 respondents answered the follow-up questionnaire.

Basic characteristics of 341 respondents

Basic characteristics of physical and mental conditions from 341 respondents

This section of the questionnaire mainly involved chronic diseases, pregnancy, regular medications, and mental health. 82.7% respondents had no chronic diseases or mental illness, and 17 respondents reported mental health conditions, details in Table 1 and supplementary table 3. In terms of the 23 respondents from the follow-up questionnaire after three-month, their mental conditions were shown in supplementary table 4. The majority of the respondents (291/341, 85.4%) did not take any medication during COVID-19, and the others took some medicine such as anti-hypertensive drugs, statins, thyroxine, immunosuppressor, anti-allergic agent and traditional Chinese medicine due to their long-standing chronic diseases.

COVID-19 impact on social situation

Regarding the economic situation, only a few (12/341, 3.5%) participants did not provide an answer. Among those who did respond, 38.9% (128/329) believed that COVID-19 influenced their lives, and more than half (201/329, 61.1%) did not think COVID-19 has impact. 138 respondents were health care workers and the rest of other people's working status and occupations during the epidemic were shown in Table 1. Twenty-eight respondents reported their behaviours changed due to COVID-19, details in Table 2. As for the 23 respondents from the follow-up questionnaire after three-month, their behavioural changes were also shown in Table 2.
Table 2

Behavioural changes caused by COVID-19 of 28 respondents since 2020 and 23 respondents in the follow-up questionnaire after three months

Items from questionnairesNever (or almost)SometimesQuite oftenVery oftenAlways (or almost)Not applicable
Respondents, Number (%)
Avoid touching other's pets1 RS# /7 (25.00) /5 (21.74)*2 (7.14) /3 (13.04)1 RS /5 (17.86) /1 (4.35)1 RS /10 (35.71) /9 (39.13)3 (10.71) /5 (21.74)1 RS /1 (3.57) /NI
Wash your hands with soap or alcohol gel before eating?NI/NI1 (3.57) /6 (26.09)2 RS /4 (14.29) /3 (13.04)12 (42.86) /5 (21.74)1 RS /11 (39.29) /7 (30.43)1 RS /NI/2 (8.70)
Wash your hands with soap or alcohol gel after you had been close to the person who was unwell?NI /NI1 RS /1 (3.57)/6 (26.09)2 RS /3 (10.71) /4 (17.39)1 RS /13 (46.43)/8 (34.78)11 (39.29)/5 (21.74)1 RS /1 (3.57) /NI
Feel that you were able to maintain social distancing (staying 2m from the person who was ill)?NI /3 (13.04)1 RS /3 (10.71) /7 (30.43)1 RS /7 (25.00) /6 (26.09)1 RS /14 (50.00) /3 (13.04)4 (14.29) /2 (8.70)1 RS /NI /2 (8.70)
Consciously avoid touching your eyes, mouth or nose?2 (7.14) /NI2 RS /6 (21.43) /9 (39.13)4 (14.29) / 1(4.35)1 RS /9 (32.14) /8 (34.78)7 (25.00) /5 (21.74)1 RS /NI /NI
Clean things that might have viruses on them (eg. doors, taps, kitchens, bathrooms)?NI /3 (13.04)1 RS /2 (7.14) /7 (30.43)1 RS /6(21.43) /3 (13.04)15 (53.57) /3 (13.04)1 RS /5 (17.86)/5 (21.74)1 RS /NI /2 (8.70)
Wear a mask or face covering (such as a scarf over your mouth)?1 RS /NI /1 (4.35)NI /3 (13.04)5 (17.86) /1 (4.35)1 RS /8 (28.57)/8 (34.78)1 RS /15 (53.57)/10 (43.48)1 RS /NI/NI
Use any other method to try and protect yourself from covid-19 infection? (eg. Diet, vitamins, nasal sprays, herbs or other medications)1 RS /3 (10.71) /11 (47.83)1 RS /3 (10.71) /4 (17.39)7 (25.00) /2 (8.70)1 RS /8 (28.57) /6 (26.09)7 (25.00) /NI1 RS /NI /NI

NI: No information

The former was obtained from 28 respondents in the formal questionnaire, while the latter numbers were obtained from 23 respondents in the follow-up questionnaire.

1 RS means the behavioural change results of one respondent with respiratory symptoms reported.

Behavioural changes caused by COVID-19 of 28 respondents since 2020 and 23 respondents in the follow-up questionnaire after three months NI: No information The former was obtained from 28 respondents in the formal questionnaire, while the latter numbers were obtained from 23 respondents in the follow-up questionnaire. 1 RS means the behavioural change results of one respondent with respiratory symptoms reported.

Diagnosis (detection of COVID-19 and related symptoms)

Up to the time of responding to the questionnaire, 85.0% respondents had completed a PCR test for COVID-19. Six respondents had been infected with SARS-COV-2 and the others (284/290, 97.9%) had a negative result, details in Table 1. 86.8% (296/341) respondents had not developed any respiratory symptoms since the beginning of the COVID-19 outbreak. 13.2% (45/341) respondents had experienced respiratory symptoms and their common symptoms are shown in Figure 2. The respiratory symptoms restricted the patient's normal activities for a maximum of 28 days, with an average of 5.95 days. These 45 respondents reported that their symptoms caused varying degrees of discomfort as the average of the symptom severity score was 4.17 (Score of 0 is the best and 10 is the worst). The average score for concern about their illness was 3.29 (Score of 0 is no concerns and 10 is extremely concerned). 60.0% (27/45) of them recovered completely with symptoms disappeared after one and two weeks. Others outcomes including improvement, no improvement, and deterioration are in Table 6.
Fig. 2

Symptoms occurred from 45 respondents during COVID-19.

Table 6

Outcomes from 45 respondents for their respiratory symptoms after one and two weeks

OutcomesAfter 1-week treatment (n=45)Number (%)After 2-week treatment (n=17)Number (%)
Recovered18 (40.00)9 (52.94)
Improved11 (24.44)4 (23.53)
Not improved3 (8.57)2 (11.76)
Deteriorated1 (6.66)1 (5.88)
Unknown course of disease2 (4.44)-
Not reported10 (22.22)1 (5.88)
Symptoms occurred from 45 respondents during COVID-19.

Treatments and outcomes (from 45 respondents for their respiratory symptoms during the first and second weeks)

Forty-five respondents with respiratory symptoms reported their therapeutic treatments and thirty respondents reported the source of treatments during the first week of their illness, detailed in Table 4 and Table 5, including mainly four types, such as modern medicine, TCM, other treatment and no treatment. Most commonly, they practiced selfcare/self-medication (17/45, 37.8%). Seven respondents combined Chinese herbal preparation or acupuncture together with modern medicine. TCM included seven kinds of Chinese herbal preparation, acupuncture and moxibustion. In terms of access to antibiotics, 66.7% (6/9) obtained by prescription from a professional, 22.2% (2/9) used what was left over from the past and 11.1% (1/9) bought it on the Internet. The treatments were used after an average of 2.66 (1-7) days of symptoms (available data from 30 respondents).
Table 4

Treatments from 45 respondents for their respiratory symptoms during the first week

TreatmentRespondents, Number (%)
Modern medicine19 (42.22)
 Painkillers, anti-inflammatories or cough and cold medicines10 (52.63)
  Acetaminophen5 (50.00)
  Compound aminophenolidine tablets3 (30.00)
  Aspirin3 (30.00)
  Ibuprofen2 (20.00)
  Other4 (40.00)
 Antibiotics9 (47.37)
  -floxacin5 (55.56)
  Cephalosporin4 (44.44)
  -cillin4 (44.44)
  -mycins3 (33.33)
  Doxycycline1 (11.11)
 Corticosteroids4 (21.05)
 Nasal spray4 (21.05)
  Hypertonic water spray1 (25.00)
  Nasal decongestant1 (25.00)
  Isotonic water spray1 (25.00)
  Unknown3 (75.00)
 Chloroquine3 (15.79)
 Antihistamine and antiallergic drugs2 (10.53)
 Inhalant2 (10.53)
  Antiasthmatic drugs in combination with corticosteroids1 (50.00)
  Bronchodilators1 (50.00)
  corticosteroids1 (50.00)
 Syrup and drops2 (10.53)
Traditional Chinese Medicine16 (35.56)
 Chinese herbal preparation16 (100.00)
  Granules5 (31.25)
   Banlangen granules1 (20.00)
   Lianhua Qingwen Granule1 (20.00)
   Shuanghuanglian granules1 (20.00)
   Xiao Chaihu Granula1 (20.00)
   Yinqiao Jiedu granules1 (20.00)
   Hospital preparations1 (20.00)
  Oral liquid5 (31.25)
   Andrographis oral liquid1 (20.00)
   Ganmaoling oral liquid1 (20.00)
   Huoxiang Zhengqi Oral Liquid1 (20.00)
   Shuanghuanglian oral liquid1 (20.00)
  Decoction4 (25.00)
   Gegen decoction1 (25.00)
   Guizhi decoction1 (25.00)
   Shegan Mahuang decoction1 (25.00)
   Unknown1 (25.00)
  Tablet2 (12.50)
   Pudilan Tablets1 (50.00)
   Vitamin C Yinqiao tablets1 (50.00)
  Oral liquid2 (12.50)
   Compound Bamboo Water1 (50.00)
   Hospital preparations1 (50.00)
  Capsule2 (12.50)
   Four seasons antiviral mixture1 (50.00)
   Zhike Capsules1 (50.00)
  Individualized treatment2 (12.50)
 Acupuncture3 (18.75)
 Moxibustion1 (6.25)
Other treatment6 (13.33)
 Food supplements3 (50.00)
  Vitamin2 (66.67)
   Vitamin B122 (100.00)
   Vitamin C2 (100.00)
   Vitamin D1 (50.00)
   Vitamin E1 (50.00)
  Omega-3 fatty acids1 (33.33)
  Mineral supplement1 (33.33)
   Calcium1 (100.00)
   Zinc1 (100.00)
  Unknown2 (66.67)
 Exercises or activities2 (33.33)
  Massage2 (100.00)
  Sauna1 (50.00)
 Special foods and diets4 (66.67)
  Fruits and vegetables3 (75.00)
   Orange2 (66.67)
   Ginger1 (33.33)
   Pepper1 (33.33)
  Fasting1 (25.00)
 Home remedies4 (66.67)
  Nasal irrigation2 (50.00)
  Sleep1 (25.00)
  Attack a vital point1 (25.00)
No special treatment13 (28.89)
Table 5

Source of Treatments used by respondents for their respiratory symptoms during the first week

Treatments prescription methodNumber (percentage among 45 respondents, %)
Respondents themselves17 (37.78)
TCM practitioners7 (15.56)
Modern-medicinal doctors5 (11.11)
Pharmacist4 (8.89)
Families and friends3 (6.67)
Internet searching1 (2.22)
Not reported15 (33.33)
Only three respondents reported that they were in the hospital for 5.5 (1-10) days on average, and they had been discharged at the time of filling out the questionnaire. Only one respondent reported confirmed as COVID-19 by SARS-CoV-2 PCR tests, the other two did not reported other chronic diseases or any reasons for being in the hospital. No one was in intensive care, and no one was on a ventilator. All respondents had improved and recovered after one or two weeks, details in Table 6. In terms of the 23 respondents from the follow-up questionnaire after three-month, two respondents reported that they had new respiratory symptoms, and their treatment and prevention were shown in supplementary table 5. Among these 45 respondents, they failed to get SARS-CoV-2 PCR test when they had respiratory symptoms in 2020, so seven respondents suspected to be infected with COVID-19 and they made possible behavioural changes to prevent the potential spread since 2020, details in Table 2. However, up to the time of responding to the questionnaire in 2021, 28.9% (13/45) respondents reported as both negative SARS-CoV-2 nucleic acid test and negative antibody testing of COVID-19, and only one respondent reported as both positive. Two respondents reported as positive SARS-CoV-2 nucleic acid test but negative antibody testing of COVID-19, and one respondent reported as negative SARS-CoV-2 nucleic acid test but positive antibody testing of COVID-19. Others (28/45, 62.2%) did not have any test for COVID-19.

Preventive measures to prevent the spread from 341 respondents

We collected all respondents’ treatments and behaviours to prevent COVID-19. 22.3% (76/341) chose TCM as a means of prevention. Lianhua Qingwen Granule [连花清瘟颗粒] was the most commonly used (13/76, 65.0%). 18.5% (63/341) chose other preventive measures such as exercise, food supplements, special foods, and home remedies, detailed in Table 7.
Table 7

Preventive measures from 341 respondents during COVID-19

Treatment categoryRespondents, Number (%)
Modern medicine18 (5.28)
  Painkillers, anti-inflammatories or cough and cold medicines6 (33.33)
  Acetaminophen1 (16.67)
  Compound aminophenolidine tablets1 (16.67)
  Aspirin3 (50.00)
  Ibuprofen2 (33.33)
  Corticosteroids1 (5.56)
  Nasal spray4 (22.22)
  Nasal decongestant1 (25.00)
  Unknown3 (75.00)
  Antihistamine and antiallergic drugs2 (11.11)
  Inhalant2 (11.11)
  Antiasthmatic drugs in combination with corticosteroids1 (50.00)
  corticosteroids1 (50.00)
  Antivirotic2 (11.11)
  Syrup and drops2 (11.11)
Traditional Chinese Medicine76 (22.29)
  Chinese herbal preparation58 (76.32)
  Granules20 (34.48)
   Lianhua Qingwen Granule13 (65.00)
   Banlangen granules4 (20.00)
   Shuanghuanglian granules3 (15.00)
   Ganmao Qingre granules2 (10.00)
   Yinqiao Jiedu granules2 (10.00)
   Yupingfeng granules2 (10.00)
   Ganmaoling granules1 (5.00)
   Huangqi granules1 (5.00)
   Jinhua Qinggan granules1 (5.00)
   Qingre Jiedu granules1 (5.00)
   Xiao Chaihu Granula1 (5.00)
   Xinxue granules1 (5.00)
   Toujie Quwen granules1 (5.00)
   Hospital preparations2 (10.00)
  Oral liquid4 (6.90)
   Huoxiang Zhengqi Oral Liquid3 (75.00)
   Unknown1 (25.00)
  Decoction26 (44.83)
   Qingfei Paidu decoction3 (11.54)
   Guizhi decoction2 (7.69)
   Huangqi Liujunzi decoction1 (3.85)
   Huopo Xialing decoction1 (3.85)
   Liujunzi decoction1 (3.85)
   Maiwei Buzhongyiqi decoction1 (3.85)
   Xiaochaihu decoction1 (3.85)
   Yinqiao Powder and Sanren decoction1 (3.85)
   Jiang Liangduo's preventive prescription2 (7.69)
   Unknown11 (42.31)
   Not reported2 (7.69)
  Tablet1 (1.72)
   Vitamin C Yinqiao tablets1 (100.00)
  Oral liquid3 (5.17)
   Hospital preparations1 (33.33)
   Not reported2 (66.67)
  Capsule11 (18.97)
   Lianhua Qingwen Capsules8 (72.73)
   Four seasons antiviral mixture2 (18.18)
   Huoxiang Zhengqi Capsule2 (18.18)
   Jinhua Qinggan Capsule2 (18.18)
   Loquat Zhike Capsules2 (18.18)
   Compound Houttuynia cordata mixture1 (9.09)
   Jinye Baidu Capsules1 (9.09)
   Qingkailing Capsules1 (9.09)
   Reyanning mixture1 (9.09)
   Tanreqing Capsules1 (9.09)
  Individualized treatment5 (8.62)
  Pills2 (3.45)
   Baohe pills1 (50.00)
    Huoxiang Zhengqi pills1 (50.00)
   Xuanbai Chengqi Soup and Ganlu Disinfectant Pills1 (50.00)
  Powder2 (3.45)
   Zhuju Baihe powder1 (50.00)
    Not reported1 (50.00)
TCM herbal tea1 (1.72)
 Acupuncture3 (3.95)
 Moxibustion21 (27.63)
 Tuina7 (9.21)
 Qigong14 (18.42)
 Taichi6 (7.89)
 Cupping2 (2.63)
 Others (not reported)3 (3.95)
Other treatment63 (18.48)
  Food supplements26 (41.27)
  Vitamin22 (84.62)
   Vitamin C13 (59.09)
   Vitamin B127 (31.82)
   Vitamin D6 (27.27)
   Vitamin E3 (13.64)
   Vitamin A2 (9.09)
   Multivitamin4 (18.18)
  Omega-3 fatty acids4 (15.38)
  Mineral supplement2 (7.69)
   Calcium2 (100.00)
   Zinc2 (100.00)
 Magnesium1 (50.00)
  Enzyme supplements2 (7.69)
  Probiotics6 (23.08)
  Unknown13 (50.00)
 Exercises or activities56 (88.89)
  Sauna9 (16.07)
  Reflexology Western Massage8 (14.29)
  Walk or hike32 (57.14)
  Sports38 (67.86)
  Sunbathing5 (8.93)
  Mindfulness Meditation8 (14.29)
  Others4 (7.14)
Special foods and diets42 (66.67)
  Fruits and vegetables37 (88.10)
   Orange20 (54.05)
   Ginger17 (45.95)
   Garlic15 (40.54)
   Carrot10 (27.03)
   Green onion10 (27.03)
   Lemon8 (21.62)
   Onion7 (18.92)
   White radish2 (5.41)
   Apple1 (2.70)
  Soup12 (28.57)
  Bee products10 (23.81)
   Honey10 (100.00)
   Bee milk1 (10.00)
   Propolis1 (10.00)
  Spice2 (4.76)
  Seaweeds2 (4.76)
  Kombucha and KEFIR2 (4.76)
  High-calorie food1 (2.38)
Home remedies23 (36.51)
  Nasal irrigation8 (34.78)
  Inhalation of vapor6 (26.09)
  Lemon and Honey6 (26.09)
  Apple vinegar5 (21.74)
  Inhalation of essential oils3 (13.04)
  Lemon juice2 (8.70)
  Wash hands regularly2 (8.70)
  Drink more water1 (4.35)
Essential oils2 (3.17)
  Lemon1 (50.00)
  Mint1 (50.00)
  Eucalyptus1 (50.00)
No special treatment229 (87.68)
As for vaccination against COVID-19, 20.8% (71/341) respondents had received the COVID-19 vaccine since November 27, 2020. The percentages of different brands of received first-dose and second-dose vaccines are shown in Table 1. People’ opinions and behaviours were influenced when the various COVID-19 vaccines are available, the results from 149 respondents was shown in Table 3. 35.6% (53/149) respondents were still worried and 46.6% (159/341) were vaccinated to prevent COVID-19. 30.8% (105/341) were vaccinated because they worked in hospitals, and 3.5% (12/341) had a need to go abroad.
Table 3

Behavioural changes of 149 respondents received COVID-19 vaccines and 21 respondents in the follow-up questionnaire after three-month

Items from questionnairesMoreA little bit moreSame as beforeSlightly LessLessNeverNot applicable
Respondents, Number (%)
In close contact with people you don't live with5 (3.36) /1 (4.76)*7 (4.70) /2 (9.52)68 (45.64) /18 (85.71)10 (6.71) /0 (0.00)20 (13.42) / 0 (0.00)24 (16.11) /0 (0.00)15 (10.07) /0 (0.00)
The number of times masks have been used in public places22 (14.77) /1 (4.76)5 (3.36) /1 (4.76)97 (65.1)/17 (80.95)4 (2.68) /2 (9.52)1 (0.67) /0 (0.00)3 (2.01) /0 (0.00)17 (11.41) /0 (0.00)
Hand washing rates20 (13.42) /0 (0.00)10 (6.71) /0 (0.00)94 (63.09) /20 (95.24)6 (4.03)/0 (0.00)0 (0.00)/1 (4.76)0 (0.00)/0 (0.00)19 (12.75) /0 (0.00)

NI: No information

The former data was obtained from 149 respondents in the formal questionnaire, while the latter numbers were obtained from 21 respondents in the follow-up questionnaire after three-month

Behavioural changes of 149 respondents received COVID-19 vaccines and 21 respondents in the follow-up questionnaire after three-month NI: No information The former data was obtained from 149 respondents in the formal questionnaire, while the latter numbers were obtained from 21 respondents in the follow-up questionnaire after three-month Treatments from 45 respondents for their respiratory symptoms during the first week Source of Treatments used by respondents for their respiratory symptoms during the first week Outcomes from 45 respondents for their respiratory symptoms after one and two weeks Preventive measures from 341 respondents during COVID-19 With regard to the results of the follow-up questionnaire from 23 respondents, 91.3% (21/23) respondents had received the first dose of COVID-19, and 82.6% (19/23) had received the second dose. The majority of respondents kept their behaviours the same as before receiving vaccines, such as hand washing rates (20/23, 95.2%), social distancing (18/23, 85.7%), and wearing masks in public places (17/23, 81.0%), details in Table 3. In addition, considering anxiety about COVID, 47.6% (10/21) respondents were much more reassured after the vaccination; 14.3% (3/21) were relieved a little, and 38.1% (8/21) had no change.

Discussion

Since 2020, COVID-19 is still currently one of the most important public health challenges to populations worldwide. Numerous studies have focused on hospitalized patients infected with novel coronavirus50, 51, 52, but there have been fewer studies on the general population in the community. Therefore, our survey has provided data from the general population in China, so as to explore and understand changes in behavioural habits and conditions of the general population during the COVID-19 pandemic in China. First and foremost, we used wjx.cn platform to support the identification of unique visitor by IP addresses, it helped to calculate the respondent rate. The response rate was only 67.8%, which seemed to be low. As the results of a meta-analysis study showed that there was a greater chance of response when patients were presented with a comparatively shorter questionnaire. This is a comprehensive survey covering diagnosis, treatment, outcome for one week and two weeks, and preventive measure. However, it takes more than 30 minutes which might be a challenge with behaviour fatigue and people reluctant to complete more surveys. People faced increasing COVID-19 questionnaires since 2020, so they may have experienced behaviour fatigue and were reluctant to complete more surveys. Furthermore, considering the online questionnaire, the respondents were particularly easily distracted during the answering process, so they could not concentrate on for a long time. For geographical distribution of respondents, we tried to include people from as many provinces and municipalities in China as possible, so only several areas were missing. Considering the interpersonal relationship of all authors and our dissemination strategy, the respondents from different geographic areas were nearly correlated to the prevalence rate of COVID-19 in various areas in 2020. The total number of respondents varied between different regions, and among them, Hubei province was the highest. This could be due to the tendency of people in Hubei province who suffered most in COVID-19 and were willing to make a contribution to scientific research. Our findings indicated that 86.8% respondents did not have any respiratory symptoms since the beginning of the COVID-19 outbreak. As China has benefited from the effective implementation of epidemic prevention and control policies, there were few cases of COVID-19 and so data collected on treatment, prevention and treatment outcomes were limited. Referring to respiratory symptoms, common clinical features of COVID-19 include fever, fatigue, cough, shortness of breath, and pneumonia. Patients with mild COVID-19 had similar symptoms to those with the common cold and required a PCR test for a definitive diagnosis. A study in the Shanghai city of China indicated that during the COVID-19 pandemic, personal protection and reduction of human gathering can also effectively reduce the infection of influenza in the population. Therefore, the above strict prevention and control measures may have a potential positive effect on both COVID-19 and influenza. Additionally, in terms of routes of transmission of COVID-19, coughing, sneezing, and touching could transmit the virus. The behavioural changes including keeping hands clean, wearing a mask and social distancing reflected that people were influenced by COVID-19 and kept away from the virus in different methods as the Table 2 and Table 3 listed. Based on the results, 45 respondents with respiratory symptoms had a good outcome. COVID-19 clinical guidelines recommended to use TCM for treatment and prevention. At the very beginning of 2020, evidence proved that TCM played an important role in improving self-resistance, regulating immunity and preventing virus, maybe including COVID-19. The main prevention principles of TCM were to tonify Qi to protect from external pathogens, disperse wind and discharge heat, and resolve dampness, by prescribing the modalities of decoction, patent remedies, acupuncture and Qigong, . Although we failed to collect enough data about TCM usage, we listed all possible TCM modalities and patent remedies recommended by clinical guidelines in supplementary table 1 and showed usage frequency. When we released the questionnaire, there were main six brands of vaccines. We found that 20.53% respondents received a COVID-19 vaccine. It would be necessary to focus on vaccine application in the future to figure more information about the common population's attitude and feedback on it. Mental health problems have been addressed from the results, as 17 respondents reported their mental health problems (supplementary table 3). A recent living systematic review of the psychological disorders in people suffering from COVID-19 showed that a high proportion of COVID-19 patients manifested psychological problems such as anxiety, depression, post-traumatic stress disorder (PTSD), insomnia, somatization, and fear. In addition to the patients with COVID-19, another study has shown that the epidemic has also caused adverse mental health consequences on the general population. Thus, further studies should not only focus on treatment of COVID-19, but also involve the negative impact on general population's mental condition. Effective psychological intervention and support are needed during the post COVID-19 epidemic. For the special population, due to limited data from nine pregnant women among our respondents, we cannot find any special treatment or prevention from them. However, the safety of pregnant women and fetuses should still be noticed, including susceptibility and prognoses and the effects of the infection on the fetuses. Previous studies have shown that the severity of the disease in pregnant women was not yet apparent, and COVID-19 did not increase the rate of miscarriage, stillbirth, preterm labor or teratogenicity, and no unequivocal evidence support the fetal infection by intrauterine vertical transmission of SARS-CoV-262, 63, 64, 65, but there are still more and more reports of maternal deaths due to COVID-19, 66, 67. Consequently, we still need to keep in mind that pregnant women and neonates require special attention regarding the prevention, diagnosis and management of COVID-19 to achieve health equity. Differing from a large number of previous clinical studies focusing on patients48, 49, 50, we aimed at a wide range of situations by following the general population in the community, so we can explore the issues from a multi-dimensional perspective. Besides, in the process of adaptation of the questionnaire, we fully considered China's national conditions, added various complementary and alternative medicines recommended according to COVID-19 clinical guidelines in the questionnaires as the options. As the TCM clinical guidelines recommended in different ares of China varied, we collected different principles of treatments according to syndrome differentiation based on TCM theories as much as possible, in order to present much potential TCM evidence. However, there were also several limitations in our study. The questionnaire sample was not as large as we had planned and the respondent rate was low. If questionnaires could have been distributed in the early stage of the outbreak, the information obtained would have been richer. Considering the majority (89.0%, 138/155) of participants who responded to the question about their occupations were healthcare workers and nearly a half of participants did not respond , we failed to recruit a representative sample of the population . If we could disseminate the survey via communities and primary care, the results and sample may be different. The primary healthcare providers could be a good way to recruit more participants. In addition, longitudinal associations can be studied in future in order to have a more comprehensive understanding of the issue, such as the association between preventative behaviour and subsequent illness, the association between treatments taken and illness outcomes, the association between disease course and mental statement, and so forth. Further exploratory analyses can inspire creative topics for future public health developments, as well as further pre-clinical and clinical research. In summary, we found evidence of widespread use of infection control behaviours and modern medicines and TCM for treatment and prevention of COVID-19 and respiratory symptoms, especially many TCM preparations recommended in Chinese clinical guidelines. The efficacy of TCM still needs to be evaluated in further robust studies. Larger scale studies including a more representative sample are needed to confirm our findings.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this article.
  36 in total

1.  COVID-19 pandemic in Yemen: A questionnaire based survey, what do we know?

Authors:  Ghulam Dhabaan; Abdullah Chahin; Abdulrahman Buhaish; Mahmoud Shorman
Journal:  J Infect Dev Ctries       Date:  2020-12-31       Impact factor: 0.968

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.

Authors:  Barbara Nussbaumer-Streit; Verena Mayr; Andreea Iulia Dobrescu; Andrea Chapman; Emma Persad; Irma Klerings; Gernot Wagner; Uwe Siebert; Dominic Ledinger; Casey Zachariah; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2020-09-15

4.  Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China.

Authors:  Tao Li; Yalan Zhang; Cheng Gong; Jing Wang; Bao Liu; Li Shi; Jun Duan
Journal:  Eur J Clin Nutr       Date:  2020-04-22       Impact factor: 4.016

5.  Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.

Authors:  Mandeep R Mehra; Frank Ruschitzka; Amit N Patel
Journal:  Lancet       Date:  2020-06-05       Impact factor: 79.321

6.  Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia.

Authors:  Huaping Zhu; Lin Wang; Chengzhi Fang; Sicong Peng; Lianhong Zhang; Guiping Chang; Shiwen Xia; Wenhao Zhou
Journal:  Transl Pediatr       Date:  2020-02

7.  Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.

Authors:  Bhagteshwar Singh; Hannah Ryan; Tamara Kredo; Marty Chaplin; Tom Fletcher
Journal:  Cochrane Database Syst Rev       Date:  2021-02-12

8.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

Authors:  Huijun Chen; Juanjuan Guo; Chen Wang; Fan Luo; Xuechen Yu; Wei Zhang; Jiafu Li; Dongchi Zhao; Dan Xu; Qing Gong; Jing Liao; Huixia Yang; Wei Hou; Yuanzhen Zhang
Journal:  Lancet       Date:  2020-02-12       Impact factor: 79.321

9.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Authors:  Feng-Cai Zhu; Yu-Hua Li; Xu-Hua Guan; Li-Hua Hou; Wen-Juan Wang; Jing-Xin Li; Shi-Po Wu; Bu-Sen Wang; Zhao Wang; Lei Wang; Si-Yue Jia; Hu-Dachuan Jiang; Ling Wang; Tao Jiang; Yi Hu; Jin-Bo Gou; Sha-Bei Xu; Jun-Jie Xu; Xue-Wen Wang; Wei Wang; Wei Chen
Journal:  Lancet       Date:  2020-05-22       Impact factor: 202.731

10.  Covid-19 pandemic and pregnancy.

Authors:  Satoshi Hayakawa; Shihoko Komine-Aizawa; Gil G Mor
Journal:  J Obstet Gynaecol Res       Date:  2020-08-10       Impact factor: 1.697

View more
  2 in total

1.  Use of Traditional, Complementary and Integrative Medicine During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.

Authors:  Tae-Hun Kim; Jung Won Kang; Sae-Rom Jeon; Lin Ang; Hye Won Lee; Myeong Soo Lee
Journal:  Front Med (Lausanne)       Date:  2022-05-09

2.  A nationwide survey on the management of the COVID-19 pandemic and respiratory disease in South Korea.

Authors:  Lin Ang; Mi Hong Yim; Eunhye Song; Hye Won Lee; Hyangsook Lee; Tae-Hun Kim; Merlin Willcox; Xiao-Yang Hu; Joelle Houriet; Bertrand Graz; Je-Won Lee; Yunho Jang; Jung Tae Kim; Eunsop Kim; Yong Hee Park; Myeong Soo Lee
Journal:  Front Med (Lausanne)       Date:  2022-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.